What is Dong-A ST Co., Ltd.'s (170900.KS) StockRank?

MoatMap's StockRank for Dong-A ST Co., Ltd. (170900.KS) is 25/100, with a Sell signal. This is a composite score combining Quality (42), Value (46), and Momentum (28) factor ranks across MoatMap's 20,000+ stock universe.

Does Dong-A ST Co., Ltd. have an economic moat?

Dong-A ST Co., Ltd. (170900.KS) has a Quality factor score of 42/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Dong-A ST Co., Ltd. a buy, hold, or sell?

MoatMap's current signal for Dong-A ST Co., Ltd. (170900.KS) is Sell, based on a StockRank of 25/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Dong-A ST Co., Ltd. in?

Dong-A ST Co., Ltd. (170900.KS) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (South Korea).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

170900.KS

SELLREMOVE

Dong-A ST Co., Ltd. · Healthcare · South Korea · $256M · Avg Vol: $519K/d

StockRank

P/E (TTM)

—

ROE

-2.5%

D/E

0.7x

Dividend %

1.9%

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Dong-A ST is a domestic-focused Korean pharmaceutical company lacking the global scale, regulatory moats, or high-utilization CDMO capabilities required to benefit from our CDMO Pricing Power theme.

COMPANY DESCRIPTION

Dong-A ST Co., Ltd. is a prominent South Korean pharmaceutical company specializing in prescription drugs, medical devices, and diagnostic systems. The company maintains a strong market position through its robust R&D pipeline, which focuses on biosimilars, endocrine treatments, and oncology therapeutics. Its extensive domestic sales network and growing international licensing agreements provide a solid foundation for long-term growth.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR
Revenue	418M	437M	459M	532M	8.4%
EPS	0.97	0.81	-0.09	-1.96	-16.7%
Shares	9M	9M	10M	10M	+4.7%
Debt	205M	268M	326M	354M	19.8%
Equity	442M	433M	441M	423M	-1.5%
Op CF	22M	2M	-8M	18M	-5.5%
Inv CF	33M	-72M	-73M	-40M	—
Fin CF	-6M	36M	57M	11M	—

PRICE (1M)-16.7%

SMA 50SMA 200

$23.60

RSI (14)

29.4

52W High

$36.54

From 52W High

0.6%

SCORE BREAKDOWN

Quality

ROIC

-2.0%42.1

ROE

-2.5%41.7

GP/Assets

25.2%57.1

Op. Margin

3.8%52.2

FCF/Assets

-2.9%40.8

Piotroski

—55.7

Int. Cover

-1.0x37.5

D/E Ratio

0.72x21.9

Current Ratio

1.50x24.7

Value

P/E (TTM)

—N/A

EV/EBITDA

14.2x29.8

P/FCF

—N/A

P/B

0.5x89.4

P/S

0.4x94.2

Div Yield

1.9%49.3

Momentum

52W High %

65%47.5

RS 6M

-151%3.0

SMA 50/200

0.91x38.6

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

—N/A

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$256M

P/E (Forward)

10.9x

Gross Margin

42.9%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 170900.KS are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
170900.KS	Dong-A ST Co., Ltd.(you)	$256M	25	SELL
003000.KS	Bukwang Pharmaceutical Co., Ltd.	$318M	30	SELL
047920.KQ	HLB Pharmaceutical Co., Ltd.	$257M	14	STRONG SELL
249420.KS	Ildong Pharmaceutical Co., Ltd.	$447M	26	SELL
019170.KS	Shinpoong Pharmaceutical Co.,Ltd	$343M	17	STRONG SELL
004310.KS	Hyundai Pharmaceutical Co., Ltd.	$117M	23	SELL
256840.KQ	BNC KOREA, Inc.	$131M	19	STRONG SELL
220100.KQ	FutureChem Co.,Ltd	$222M	6	STRONG SELL
214390.KS	Kyongbo Pharmaceutical Co., Ltd	$91M	27	SELL
003520.KS	Yungjin Pharm. Co., Ltd.	$158M	10	STRONG SELL

Peer medians: ROE -1.1% · P/E 17.7x · Gross margin 43.6%

Dong-A ST Co., Ltd. (170900.KS) — Stock Score Summary

Dong-A ST Co., Ltd. (170900.KS) has a MoatMap StockRank of 25/100 based on Quality (42/100), Value (46/100), and Momentum (28/100) factor scores. The current signal is SELL. Dong-A ST is a domestic-focused Korean pharmaceutical company lacking the global scale, regulatory moats, or high-utilization CDMO capabilities required to benefit from our CDMO Pricing Power theme.

Key Financial Metrics

Price	$23.60
Market Cap	$256M
P/E (Forward)	10.86
Price/Book	0.54
Return on Equity	-2.5%
Return on Invested Capital	-2.0%
Debt/Equity	72.19
Gross Margin	42.9%
Operating Margin	3.8%
Revenue Growth	11.8%
Dividend Yield	1.9%
Free Cash Flow	$-18K

Dong-A ST Co., Ltd. operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector (South Korea).

Frequently Asked Questions

What is Dong-A ST Co., Ltd.’s (170900.KS) StockRank?: MoatMap’s StockRank for Dong-A ST Co., Ltd. (170900.KS) is 25/100, with a Sell signal. It is a composite of Quality (42), Value (46), and Momentum (28) factor ranks across MoatMap’s 20,000+ stock universe.
Does Dong-A ST Co., Ltd. have an economic moat?: Dong-A ST Co., Ltd. (170900.KS) has a Quality factor score of 42/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Dong-A ST Co., Ltd. a buy, hold, or sell?: MoatMap’s current signal for Dong-A ST Co., Ltd. (170900.KS) is Sell, based on a StockRank of 25/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Dong-A ST Co., Ltd. in?: Dong-A ST Co., Ltd. (170900.KS) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (South Korea).